For patients with symptomatic illness demanding therapy, ibrutinib is commonly recommended according to four stage III randomized medical trials comparing ibrutinib with chlorambucil monotherapy106 together with other typically applied CIT mixtures, particularly FCR, bendamustine as well as rituximab and chlorambucil moreover obinutuzumab (ClbO).10… Read More